ONCOLOGY PHARMA INC - ONPH STOCK NEWS

Oncology Pharma Inc. (OTC PINK:ONPH) is advancing its Nanoemulsion Drug Delivery System through an ongoing financing review. This innovative technology enhances bioavailability and tumor localization of anticancer drugs, addressing issues related to low solubility and adverse side effects of existing treatments. The company also explores initial FDA application feasibility, emphasizing its commitment to oncology advancements. Despite potential benefits, risks include negative cash flows, funding needs, and uncertainties in regulatory acceptance and market adoption.

Oncology Pharma Inc. (OTC PINK:ONPH) has successfully completed the initial feasibility stage of its nanoemulsion drug delivery system project, demonstrating acceptable results to proceed further. The study focused on dactinomycin encapsulated in lipid nanoemulsions, with key findings including:

• Nanoparticle size of approximately 200 nm for improved delivery.
• Stable nanoparticles at 40°C.
• 100% incorporation of dactinomycin.
• 50% drug retention at 3 hours.

The company is committed to advancing its project, including potential FDA applications.

Oncology Pharma Inc. (OTC PINK:ONPH) announced its collaboration with Connect2Trials, Inc., a spinoff from Ribera Solutions, to enhance patient engagement in clinical trials. The Company is committed to supporting Connect2Trials in developing a patient engagement portal and expects to commercialize within the next quarter, contingent on financing. A prototype is scheduled for late June 2022, aiming to attract top pharmaceutical clients. This initiative addresses challenges in patient retention during trials, positioning Oncology Pharma as a key player in clinical trial engagement.

Oncology Pharma Inc. (OTC PINK:ONPH) announced the successful completion of the initial feasibility phase for its licensed dactinomycin nanoemulsion. This milestone is a crucial step in proving the ability to produce drug formulations with improved delivery characteristics. Early data indicates that the nanoemulsion can maintain stability for weeks, with potential for several months. The aim is to enhance the safety profile of dactinomycin, a potent cancer drug, by providing controlled drug release. Further development discussions are ongoing, with promising formulations identified for advancement.

Oncology Pharma Inc. (OTC PINK:ONPH) announced progress in its investment with Ribera Solutions, which has now become an independent entity named Connect2Trials, Inc.. The company is developing a patient retention platform to enhance clinical trial participation and engagement. Oncology Pharma aims to finance further development to secure significant interest in Connect2Trials. The prototype is expected by late March 2022, with pilot deployments planned for Q2 2022. Challenges such as financing and operational cash flows remain.

Oncology Pharma Inc. (OTC PINK:ONPH) announced progress on studies under its Co-Development Agreement with NanoSmart Pharmaceuticals, focusing on enhancing safety and localization of dactinomycin formulations for cancer treatment. The B-3 formulation lacks large aggregates and is suitable for characterization studies. The company explores pediatric cancer applications, aiming for FDA approval post-Phase II trials. It also highlights a multidrug nanoemulsion platform for improved treatment efficacy. Oncology Pharma targets the underserved pediatric market, enhancing its competitive position.

Oncology Pharma Inc. (OTC PINK:ONPH) announced improvements in its formulation studies for the anticancer drug dactinomycin in collaboration with NanoSmart Pharmaceuticals. The studies showed promising results in drug incorporation and retention. Notably, formulations demonstrated over 95% drug incorporation and a time-release profile, although aggregation issues were observed in some formulations. The company aims to target the underserved pediatric market, enhancing its potential in cancer therapy. Ongoing feasibility studies indicate a commitment to commercial development.

Oncology Pharma (OTC PINK:ONPH) and Regen BioPharma (OTC PINK:RGBP, RGBPP) announced a collaboration to accelerate the development of therapeutic mRNA vaccines for treating pancreatic cancer. ONPH has exclusive rights to the commercial development of these vaccines, which utilize modified mRNA to boost the immune response against cancer. The joint effort will focus on IND-enabling studies, with Regen providing scientific expertise. The project faces contingencies including securing financing and final agreement terms. The advancement of this technology could positively impact pancreatic cancer treatment.

Oncology Pharma Inc. (OTC PINK:ONPH) announced progress in its co-development agreement with NanoSmart, revealing that recent formulations exhibit improved safety and localization for cancer therapeutics. Key findings include:

• Over 95% drug incorporation in initial formulations.
• Retention of 50% drug after 3 hours, suggesting a viable time-release profile.
• Continued research on dactinomycin formulations shows promising loading and retention.

The proprietary nanoemulsion may offer extended shelf-life and adaptability for various lipophilic cancer drugs.